Mocetinostat Completed Phase 2 Trials for Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00359086Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma